An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than among those taking placebos or other diabetes medications.
An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than among those taking placebos or other diabetes medications.
<iframe src="https://hindustansphere.com/embed/cluster/add5321e3320fe4e7beda25849e462df39719718" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know"></iframe>
An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than among those taking placebos or other diabetes medications.
